How do you decide between continuous or time-limited therapy for CLL?

During the ESH Translational Research Conference, the Lymphoma Hub was pleased to speak with Anthony Mato, Memorial Sloan Kettering Cancer Center, New York, US. We asked, How do you decide between continuous or time-limited therapy for CLL?

Mato begins by outlining the current continuous treatment approaches, as well as next-generation agents acalabrutinib and zanubrutinib. Mato goes on to discuss venetoclax combinations as time-limited approaches, and the lack of long-term data on venetoclax compared with BTK inhibitors. Finally, Mato discusses how the decision between continuous or long-term approaches should take the individual patient into consideration.